"Antifungal Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues.
| Descriptor ID |
D000935
|
| MeSH Number(s) |
D27.505.954.122.136
|
| Concept/Terms |
Antifungal Agents- Antifungal Agents
- Agents, Antifungal
- Therapeutic Fungicides
- Fungicides, Therapeutic
|
Below are MeSH descriptors whose meaning is more general than "Antifungal Agents".
Below are MeSH descriptors whose meaning is more specific than "Antifungal Agents".
This graph shows the total number of publications written about "Antifungal Agents" by people in this website by year, and whether "Antifungal Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2006 | 2 | 0 | 2 |
| 2008 | 2 | 0 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 2 | 0 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 2 | 1 | 3 |
| 2017 | 0 | 2 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 2 | 2 |
| 2020 | 4 | 1 | 5 |
| 2021 | 0 | 2 | 2 |
| 2022 | 1 | 2 | 3 |
| 2023 | 0 | 3 | 3 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antifungal Agents" by people in Profiles.
-
Antifungal activity of human antimicrobial peptides targeting apoptosis in Candida auris. J Med Microbiol. 2024 May; 73(5).
-
Impact of prior cryptococcal antigen screening on in-hospital mortality in cryptococcal meningitis or fungaemia among HIV-seropositive individuals in South Africa: a cross-sectional observational study. Clin Microbiol Infect. 2023 Aug; 29(8):1063-1069.
-
Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris: Results from a Phase 2 Trial. Antimicrob Agents Chemother. 2023 05 17; 67(5):e0141922.
-
Neonatal invasive candidiasis in low- and middle-income countries: Data from the NeoOBS study. Med Mycol. 2023 Mar 02; 61(3).
-
Fungicidal activity of human antimicrobial peptides and their synergistic interaction with common antifungals against multidrug-resistant Candida auris. Int Microbiol. 2023 May; 26(2):165-177.
-
Outcomes of flucytosine-containing combination treatment for cryptococcal meningitis in a South African national access programme: a cross-sectional observational study. Lancet Infect Dis. 2022 09; 22(9):1365-1373.
-
Quorum Sensing and Biofilm Disrupting Potential of Imidazole Derivatives in Chromobacterium violaceum Using Antimicrobial and Drug Discovery Approaches. Braz J Microbiol. 2022 Jun; 53(2):565-582.
-
Clade distribution of Candida auris in South Africa using whole genome sequencing of clinical and environmental isolates. Emerg Microbes Infect. 2021 Dec; 10(1):1300-1308.
-
Etest ECVs/ECOFFs for Detection of Resistance in Prevalent and Three Nonprevalent Candida spp. to Triazoles and Amphotericin B and Aspergillus spp. to Caspofungin: Further Assessment of Modal Variability. Antimicrob Agents Chemother. 2021 10 18; 65(11):e0109321.
-
Mezoneuron benthamianum inhibits cell adherence, hyphae formation, and phospholipase production in Candida albicans. Arch Microbiol. 2020 Nov; 202(9):2533-2542.